A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
Eisai Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Henan Cancer Hospital
Takeda
Rigshospitalet, Denmark
Brown University
Sanofi
Barbara Ann Karmanos Cancer Institute
Peking University First Hospital
SWOG Cancer Research Network
Checkpoint Therapeutics, Inc.